SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

FRASSOLDATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.730
EU - Europa 1.133
AS - Asia 1.062
OC - Oceania 6
SA - Sud America 4
AF - Africa 2
Totale 7.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.719
CN - Cina 507
IT - Italia 311
SG - Singapore 237
TR - Turchia 174
PL - Polonia 168
DE - Germania 150
UA - Ucraina 144
GB - Regno Unito 130
SE - Svezia 118
ID - Indonesia 80
BE - Belgio 30
VN - Vietnam 28
FI - Finlandia 16
CZ - Repubblica Ceca 14
FR - Francia 11
NL - Olanda 11
IN - India 10
JP - Giappone 9
CA - Canada 6
IE - Irlanda 6
IR - Iran 6
AU - Australia 5
ES - Italia 5
MX - Messico 5
AT - Austria 4
HK - Hong Kong 4
RO - Romania 4
CH - Svizzera 3
BR - Brasile 2
CL - Cile 2
KR - Corea 2
NO - Norvegia 2
EG - Egitto 1
IL - Israele 1
IM - Isola di Man 1
KH - Cambogia 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 7.937
Salva come PNG Salva come JPEG
Città #
Fairfield 868
Woodbridge 751
Houston 456
Ashburn 418
Chandler 416
Seattle 348
Wilmington 327
Ann Arbor 321
Cambridge 304
Jacksonville 253
Singapore 168
Warsaw 168
Izmir 158
Beijing 120
Princeton 104
Nanjing 96
Jakarta 80
Ferrara 78
New York 53
Boardman 51
San Diego 51
Shanghai 49
Milan 40
Nanchang 36
Falls Church 35
Dearborn 32
Hebei 32
Los Angeles 32
Brussels 30
Santa Clara 26
Dong Ket 25
Redwood City 23
Shenyang 23
London 21
Tianjin 20
Des Moines 18
Norwalk 18
Changsha 17
Bremen 16
Bologna 13
Jiaxing 13
Guangzhou 11
Kunming 11
Mountain View 11
Addison 10
Brno 9
Kilburn 9
Redmond 9
Chicago 6
Edinburgh 6
Ferrara di Monte Baldo 6
Hefei 6
Helsinki 6
Orange 6
San Mateo 6
Tokyo 6
Washington 6
Dublin 5
Jinan 5
La Jolla 5
Tappahannock 5
Fuzhou 4
Hangzhou 4
Hong Kong 4
Hounslow 4
Munich 4
Philadelphia 4
Toronto 4
Verona 4
Vienna 4
Zhengzhou 4
Changchun 3
Chiswick 3
Indiana 3
Las Vegas 3
Mexico 3
Monmouth Junction 3
Ningbo 3
Padova 3
Parma 3
Pittsburgh 3
Rome 3
Saint Louis 3
Wandsworth 3
Agrigento 2
Ancona 2
Baldissero Torinese 2
Bonate Sopra 2
Brescia 2
Cleveland 2
Dalian 2
Davis 2
Delhi 2
Duncan 2
Florence 2
Focsani 2
Frankfurt Am Main 2
Frosolone 2
Genazzano 2
Hanoi 2
Totale 6.363
Salva come PNG Salva come JPEG
Nome #
Absolute quantification of cell-free microRNAs in cancer patients 182
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 169
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR 165
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 163
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 157
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 148
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 141
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study 136
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 126
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 125
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial) 124
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study 117
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy 115
Gastrointestinal stromal tumors and other malignancies: A case series 111
Current views on anthracycline cardiotoxicity 111
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion 107
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases 106
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 106
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature 102
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 101
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 100
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience 99
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up 99
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study 98
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients 97
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 97
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights 97
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study 96
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 94
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study 94
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results 93
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) 93
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab 93
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists 92
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective 90
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer 90
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 90
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients 89
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer 89
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out 89
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy 89
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 88
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? 88
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results 88
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives 87
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial 87
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 87
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study 87
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278) 85
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 85
Gene expression profiling in breast cancer: A clinical perspective 84
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione 83
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 80
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? 79
The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in suspected recovery of breast cancer disease: comparison with Radiological Imaging and impact on patient management 78
null 77
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 77
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer 77
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway 76
Changes of biological features in breast cancer cells determined by primary chemotherapy 74
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 74
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 72
Estrogen receptor mutation: a new strategy to overcome endocrine resistance 69
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 67
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 65
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 63
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 63
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 62
Pattern of distant recurrence according to the molecular subtypes identified by immunohistochemistry in women with early breast cancer 60
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 58
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer 56
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study 55
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 55
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 54
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 53
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 51
The role of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in patients with breast cancer recurrence: a comparison to conventional imaging (CI) techniques and clinical impact on patient management 49
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis 49
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer 48
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 48
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 47
Gli standard oncologici nel Percorso Diagnostico Terapeutico Assistenziale del paziente con carcinoma del colon: Dati del biennio 2009-2010 presso l'UO di Oncologia Clinica dell'AOU di Ferrara 46
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? 45
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 45
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma 40
Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways 39
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 36
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 35
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study 34
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 34
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 32
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 31
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 31
How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer 30
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 29
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 28
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program 28
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 25
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 25
Fighting cancer in coronavirus disease era: Organization of work in medical oncology departments in Emilia Romagna region of Italy 23
Totale 8.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.616 0 0 75 302 148 241 208 167 185 147 84 59
2020/20211.454 64 86 63 133 71 154 56 165 104 254 167 137
2021/2022844 33 48 53 22 26 109 76 42 57 109 48 221
2022/20231.024 116 59 60 112 134 133 49 124 119 11 71 36
2023/2024582 55 70 27 19 42 88 25 52 12 15 19 158
2024/2025362 70 76 216 0 0 0 0 0 0 0 0 0
Totale 8.203